Story thread · 2 reports / 2 sources
FDA Approves First Treatment for MCT8 Deficiency
fda.gov · 19h · first report
How the coverage leans
Across 2 sources · syndicated copies counted once
The U.S. Food and Drug Administration today approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in patient
The coverage
- FDA approves 1st treatment for rare genetic thyroid disorder
beckershospitalreview.com · 2h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.